C
알피바이오
314140KOSDAQ의약품 제조업54.5 / 100
Reference Date: 2026-06-10
Financial Score27.0 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but Revenue is on a declining trend. Declined 15.0% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Alpibio produces and sells pharmaceuticals (cold medicine, pain relievers) and health functional foods (omega-3, diet supplements) in various forms, including soft capsules, through OEM/ODM models. It holds over 60% of the domestic pharmaceutical soft capsule market and is rapidly growing its health functional food sales, driven by market expansion and R&D efforts with numerous patents.
Number of Employees
534people
Average Salary
37.6M KRW
Score Calculation Basis
Detailed Financial Score
PER
9.67Industry Average 11.935.0Point
In line with industry avg
PBR
0.42Industry Average 0.897.0Point
Half of industry avg (excellent)
ROE
4.47Industry Average 4.014.0Point
In line with industry avg
Debt Ratio
4.34Industry Average 12.436.5Point
Half of industry avg (excellent)
Trend 2023~20254.5 / 10 points
Revenue Growth Rate
0.5 / 3
Avg ▼4.0% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲361.4% (2-year basis)
ROE Trend
1.0 / 4
Avg ROE 3.1% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (5%, downtrend)
Current 5,230Won52-week high 8,01052-week low 5,060
1-month return1.0Point
1m -14.96% (falling)
Volume trend3.0Point
Volume flat
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral분기보고서 (2026.03)2026-05-15